Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. During the same period last year, the firm posted ($0.28) earnings per share. Acumen Pharmaceuticals Stock Performance Shares of ABOS stock […]
HC Wainwright reissued their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a report released on Wednesday, Benzinga reports. The brokerage currently has a $15.00 price target on the stock. Acumen Pharmaceuticals Stock Performance ABOS stock traded down $0.04 during trading hours on Wednesday, reaching $3.76. The stock had a trading […]
HC Wainwright restated their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $15.00 target price on the stock. Acumen Pharmaceuticals Stock Performance Shares of NASDAQ ABOS traded down $0.04 during trading on Wednesday, hitting $3.76. The company […]
Intrepid Financial Planning Group LLC acquired a new stake in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,000 shares of the company’s stock, valued at approximately $54,000. A number of other institutional investors also […]
HC Wainwright reissued their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) in a research report report published on Tuesday, Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Acumen Pharmaceuticals’ Q1 2023 earnings at ($0.31) EPS, Q2 2023 earnings at ($0.31) […]